Group 1 - The company is holding its first extraordinary general meeting of shareholders on January 30, 2026, to discuss adjustments to the use of raised funds [2][5] - The board of directors approved a proposal to adjust the use of raised funds, reducing the investment in the nutrition health raw material production base project from 206.29 million to 107.80 million yuan, reallocating the difference to new projects [2][8] - The company decided to cancel the changes related to the nutrition health raw material production base project, ensuring that all raised funds will still be directed to the original investment project [3][9] Group 2 - The adjusted allocation of raised funds will account for 20.76% of the company's net raised funds, and the changes do not constitute a related party transaction [4][11] - The board agreed to submit the adjusted proposal to the extraordinary general meeting for approval, while the original proposal will not be submitted again [4][14] - The meeting will take place at the company's office in Shanghai, with provisions for online voting through the Shanghai Stock Exchange's system [5][6]

每经AI快讯，技源集团1月14日晚间发布公告称，2026年1月14日，公司召开第二届董事会审计委员会 第四次会议和第二届董事会第七次会议，审议通过《关于变更部分募集资金用途的议案》。为提升募集 资金使用效率，同时根据公司发展规划，公司拟变更部分募投项目。公司计划将用于技源集团营养健康 原料生产基地建设项目的募集资金由约2.06亿元调减至约1.08亿元，差额部分分别用于新增的技源集团 精加工优化原料扩产建设项目7000万元和HMB关键原材料及副产品综合利用建设项目3000万元。募集 资金投入不足部分将使用自有或自筹资金，根据市场情况合理安排建设。 每经头条（nbdtoutiao）——海利生物增值9倍并购的企业，估值8个月"腰斩"，其第一大客户竟是尚未 成立的公司，离奇的事还不少…… （记者 王晓波） ...

Core Viewpoint - The company, 技源集团, is utilizing its own funds and bank acceptance bills to pay for part of the fundraising projects and will replace these with raised funds in an equivalent amount, which is deemed to optimize the payment method for fundraising projects and improve fund utilization efficiency [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission for its initial public offering, issuing 50.01 million shares at a price of 10.88 yuan per share, raising a total of 544.11 million yuan, with a net amount of 479.82 million yuan after deducting issuance costs of 64.29 million yuan [1][2]. Investment Project Situation - The net raised funds will be allocated to specific projects, including the construction of a health raw material production base and the expansion of a health food production line, with total planned investment of 602.73 million yuan and adjusted fundraising amount of 479.82 million yuan [2]. Reasons for Using Own Funds - The company has encountered operational challenges that necessitate the use of its own funds and bank acceptance bills for initial payments, primarily due to the complexity of managing payroll and other expenses through multiple bank accounts, which could violate regulatory requirements [2][3]. Payment Process - The company plans to use its own funds and bank acceptance bills for project payments and will periodically replace these with raised funds, ensuring that the funds used are treated as project funds, following a structured approval process [4]. Impact on the Company - The approach of using own funds and bank acceptance bills is expected to enhance fund utilization efficiency and reduce financial costs, aligning with the interests of the company and its shareholders without affecting normal operations or project implementation [5]. Review Procedures - The company’s board and supervisory committee have approved the use of own funds and bank acceptance bills for project payments, confirming that the necessary decision-making processes were followed and that the actions comply with relevant regulations [5][6]. Special Opinions - The supervisory committee supports the decision, stating that it adheres to necessary procedures and optimizes payment methods, benefiting the company and shareholders without altering the direction of raised funds [5]. Sponsor's Verification Opinion - The sponsor has verified that the company’s actions comply with regulatory requirements and do not harm the interests of the company or its shareholders, expressing no objections to the use of own funds and bank acceptance bills for project payments [5].

Core Points - The company, 技源集团, has adjusted the amount allocated for certain fundraising projects due to the actual net fundraising amount being lower than initially planned [1][2] - The total amount raised through the public offering was 54,410.88 million RMB, with a net amount of 47,981.82 million RMB after deducting issuance costs [1][2] - The adjustment aims to ensure the smooth implementation of fundraising projects and efficient use of funds without changing the intended use of the raised funds [2][4] Fundraising Basic Situation - The company was approved by the China Securities Regulatory Commission for its initial public offering, issuing 50.01 million shares at a price of 10.88 RMB per share [1] - The total planned investment amount disclosed in the prospectus was 60,272.93 million RMB, which exceeds the actual net amount raised [2] Adjustment of Fundraising Investment Projects - The company plans to adjust the amount allocated to the working capital project while maintaining the total investment amount of 60,272.93 million RMB [2] - The adjustment is necessary to align with the actual net fundraising amount of 47,981.82 million RMB [2] Impact of the Adjustment - The adjustment will not materially affect the normal use of the raised funds and does not change the intended use or harm shareholder interests [3][4] - The decision aligns with the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange, supporting the company's future development strategy [4] Review Procedures - The adjustment was approved by the company's board of directors and supervisory board, following necessary approval procedures [3][4] - The supervisory board supports the adjustment, emphasizing its necessity for efficient fund usage and project implementation [3][4] Sponsor's Verification Opinion - The sponsor, 东方证券, confirms that the adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [4]